By Matt Grossman

 

Bristol Myers Squibb Co. and Exelixis Inc. will get a priority review on applications with the Food and Drug Administration for combining Bristol's Opdivo and Exelixis's Cabometyx drugs to treat kidney cancer, the companies said Monday.

In a recent Phase 3 trial, the combination showed significant improvements in treating advanced renal-cell carcinoma compared with sunitinib, another drug. The trial, which included 651 patients, showed that the Opdivo-Cabometyx combination was associated with better health-related quality of life at most intervals, Bristol and Exelixis said.

The FDA has given the companies' applications for the combination treatment a target action date of Feb. 20.

In the U.S., Opdivo and Cabometyx have been approved on their own to treat cancers.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

October 19, 2020 07:33 ET (11:33 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Bristol Myers Squibb Charts.